** Drug developer Dermata Therapeutics' DRMA.O shares rise 8.2% to $1.46 premarket
** Company says its experimental drug xyngari meet primary main goal to treat moderate-to-severe acne in a late-stage study
** Main goals of the late-stage study were to measure the average change in both inflammatory and non-inflammatory skin blemishes and to assess the treatment response using a common scale called Investigator Global Assessment $(IGA)$
** Company says xyngari showed "highly statistically significant and clinically meaningful improvement" in acne compared to placebo after 12 weeks of once-weekly treatment
** Company says it is set to launch the drug in H2 2025
** As of last close, Dermata's shares down ~78% in past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.